These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 31445741)

  • 1. Letter to the Editor about Sorich et al.
    Mezquita L; Auclin E; Besse B
    J Thorac Oncol; 2019 Sep; 14(9):e209. PubMed ID: 31445741
    [No Abstract]   [Full Text] [Related]  

  • 2. Response to the Letter to the Editor: Lung Immune Prognostic Index for Outcome Prediction to Immunotherapy in Patients With NSCLC.
    Sorich MJ; Rowland A; Karapetis CS; Hopkins AM
    J Thorac Oncol; 2019 Sep; 14(9):e208. PubMed ID: 31445740
    [No Abstract]   [Full Text] [Related]  

  • 3. Author's Reply.
    Sorich MJ; Rowland A; Karapetis CS; Hopkins AM
    J Thorac Oncol; 2019 Sep; 14(9):e210. PubMed ID: 31445742
    [No Abstract]   [Full Text] [Related]  

  • 4. Toward customized trastuzumab in HER-2/neu-overexpressing non-small-cell lung cancers.
    Rosell R
    J Clin Oncol; 2004 Apr; 22(7):1171-3. PubMed ID: 14981109
    [No Abstract]   [Full Text] [Related]  

  • 5. Cetuximab in NSCLC: another trial needed.
    Perrone F
    Lancet Oncol; 2011 Jan; 12(1):3-4. PubMed ID: 21169059
    [No Abstract]   [Full Text] [Related]  

  • 6. Immunity in medicine.
    Saeed M
    J Pak Med Assoc; 2004 Sep; 54(9):496-7. PubMed ID: 15518378
    [No Abstract]   [Full Text] [Related]  

  • 7. Necitumumab in squamous non-small-cell lung cancer: how to move forward?
    Garrido P; Palacios J
    Ann Oncol; 2016 Aug; 27(8):1374-6. PubMed ID: 27329250
    [No Abstract]   [Full Text] [Related]  

  • 8. Therapeutic targeting of epidermal growth factor receptor with monoclonal antibodies.
    Siena S; Artale S; Vanzulli A; Marrapese G; Bevilacqua L; Secondino S; Sironi O; Schiavo R; Moroni M; Pedrazzoli P
    Suppl Tumori; 2002; 1(4):S46-8. PubMed ID: 12415818
    [No Abstract]   [Full Text] [Related]  

  • 9. Bevacizumab for non-small-cell lung cancer.
    Sonpavde G
    N Engl J Med; 2007 Mar; 356(13):1374; author reply 1374-5. PubMed ID: 17396304
    [No Abstract]   [Full Text] [Related]  

  • 10. Bevacizumab for non-small-cell lung cancer.
    Sculier JP; Meert AP; Paesmans M
    N Engl J Med; 2007 Mar; 356(13):1373-4; author reply 1374-5. PubMed ID: 17396306
    [No Abstract]   [Full Text] [Related]  

  • 11. Bevacizumab for non-small-cell lung cancer.
    Garassino MC; Hollander L; Torri V
    N Engl J Med; 2007 Mar; 356(13):1373; author reply 1374-5. PubMed ID: 17392310
    [No Abstract]   [Full Text] [Related]  

  • 12. Bevacizumab/chemotherapy in non-small-cell lung cancer: looking for a few good men?
    Herbst RS
    Clin Lung Cancer; 2008 Mar; 9(2):75-6. PubMed ID: 18501092
    [No Abstract]   [Full Text] [Related]  

  • 13. Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role?
    Kalemkerian G
    J Clin Oncol; 2005 Feb; 23(6):1325-6; author reply 1326-7. PubMed ID: 15718337
    [No Abstract]   [Full Text] [Related]  

  • 14. Plasma Tumor Mutation Burden and Response to Pembrolizumab-Letter.
    Li X; Xu Y; Wang G; Li L
    Clin Cancer Res; 2020 Jul; 26(13):3491. PubMed ID: 32611625
    [No Abstract]   [Full Text] [Related]  

  • 15. Authors' response to letter to the editor.
    Stopeck A; Henry D; Dansey R; Qian Y; Cong Z; Arellano J
    J Med Econ; 2013; 16(2):262-3. PubMed ID: 23424726
    [No Abstract]   [Full Text] [Related]  

  • 16. Bevacizumab in lung cancer: hurdles in clinical development.
    Pirker R
    Lancet Oncol; 2010 Aug; 11(8):703-4. PubMed ID: 20650687
    [No Abstract]   [Full Text] [Related]  

  • 17. Bevacizumab extends survival for patients with nonsquamous non-small-cell lung cancer.
    Belani CP; Ramalingam S
    Clin Lung Cancer; 2005 Mar; 6(5):267-8. PubMed ID: 15845175
    [No Abstract]   [Full Text] [Related]  

  • 18. Lung cancer in 2016: immunotherapy comes of age.
    Mitchell PL; John T
    Lancet Respir Med; 2016 Dec; 4(12):947-949. PubMed ID: 27890503
    [No Abstract]   [Full Text] [Related]  

  • 19. Lung Immune Prognostic Index for Outcome Prediction to Immunotherapy in Patients With NSCLC.
    Xu Z; Yan Y; Wang X; Zeng S; Gong Z
    J Thorac Oncol; 2019 Sep; 14(9):e207-e208. PubMed ID: 31445739
    [No Abstract]   [Full Text] [Related]  

  • 20. Bevacizumab for non-small-cell lung cancer.
    Oxnard GR
    N Engl J Med; 2007 Mar; 356(13):1373; author reply 1374-5. PubMed ID: 17396305
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.